Orion Pharma Scandinavia is a pioneering pharmaceutical company founded in 1917 in Sweden. With a focus on well-being and innovation, Orion has established itself as a prominent player in the Biotechnology, Health Care, and Pharmaceutical industries. The company prides itself on fostering a work environment that values individuality and genuine commitment, attributing its success to the dedication of its 3,600 employees. Orion's diverse portfolio encompasses originator medicines, generics, biosimilars, as well as personal care and skin care products. The company's therapeutic areas range from asthma/COPD and neurology to cardiology and gastroenterology. Orion's robust pharmaceutical R&D primarily centers around oncology and pain, with a suite of proprietary and generic medicines addressing critical medical needs. In 2023, the company recorded net sales of EUR 1,190 million and its A and B shares are publicly listed on Nasdaq Helsinki. With its commitment to creating value for society, healthcare, and patients, Orion Pharma Scandinavia stands as a leading force in the pharmaceutical landscape.
For more information, visit www.orionpharma.se
There is no investment information
No recent news or press coverage available for Orion Pharma Scandinavia.
We care about your data, and we'd love to use cookies make your experience better.
